Rivaroxabán y prurito(Pag. e96-97)

  1. A.L. Aguilar-Shea 1
  2. C. Gallardo-Mayo 2
  1. 1 Centro de Salud Puerta de Madrid, Atención Primaria de Madrid, Alcalá de Henares, Madrid, España
  2. 2 Hospital Universitario Infanta Leonor, Madrid, España
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2018

Issue: 4

Pages: 295-295

Type: Article

DOI: 10.1016/J.SEMERG.2017.12.007 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Bibliographic References

  • J.A. Ibáñez Pérez de Viñaspre, J. Gómez Bitrian, R. Royo Hernández, M. de Azúa Jiménez, C. Marco López, L. Urieta González Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs? Semergen (2017), 10.1016/j.semerg.2017.06.002 [Article in Spanish]. pii: S1138-3593(17)30219-8 Google Scholar
  • V. Barrios, C. Escobar, J.M. Lobos, J. Polo, D. Vargas Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study Semergen, 43 (2017), pp. 477-485 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P. Gorzelak-Pabiś, I. Duraj, L. Szlagowska, A. Ciastkowska, M. Broncel Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation Pol Merkur Lekarski, 37 (2014), pp. 261-264 [Article in Polish] View Record in ScopusGoogle Scholar
Data source: Dialnet